Brand Name

Priftin

Generic Name
Rifapentine
View Brand Information
FDA approval date: February 08, 2017
Classification: Rifamycin Antimycobacterial
Form: Tablet

What is Priftin (Rifapentine)?

PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis caused by Mycobacterium tuberculosis in combination with one or more antituberculosis drugs to which the isolate is susceptible.

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Shortened Regimen for Drug-susceptible TB in Children

Summary: While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as ease caregiver strain from managing treatment side effects and supporting children over many months. The primary objectiv...

Clinical Efficacy of a Short-course Regimen for Asymptomatic Tuberculosis in China

Summary: This study is a randomized controlled trial among asymptomatic tuberculosis individuals aiming to assess whether the standard treatment duration can be shortened to 17 weeks without increasing the types or doses of anti-tuberculosis medications or 13 weeks with the high-dose rifapentine and moxifloxacin.

SSTARLET: Shorter and Safer Treatment Regimens for Latent TB

Summary: Our study rationale is based on: 1. Tuberculosis Preventive Treatment (TPT) is given to healthy people and needs to be safe; 2. Tuberculosis Preventive Treatment (TPT) with shorter regimens are superior with respect to acceptance, completion, and costs; 3. 4 months of Rifampin 10mg/kg (4R10) is the safest regimen, but is completed by \<80% of patients; 4. The safety of 2 months of Rifampin 20mg/kg...